SCHEMBL2494865

SCHEMBL2494865

O=C(Nc1ccc(Cl)c(CNc2cnc(Nc3cccnc3)nc2)c1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 4/20 0.65
BTK Q06187 11/20 0.60
BRAF P15056 3/20 0.55
LCK P06239 6/20 0.55
MEN1 O00255 1/20 0.55
TSHR P16473 1/20 0.55
KMT2A Q03164 1/20 0.55
KCNQ3 O43525 2/20 0.53
KCNQ2 O43526 2/20 0.53
KCNE1 P15382 2/20 0.53
KCNQ1 P51787 2/20 0.53
KCNQ5 Q9NR82 1/20 0.52
EPHX2 P34913 1/20 0.52
BLK P51451 2/20 0.52
JAK2 O60674 1/20 0.51
PDGFRB P09619 1/20 0.51
FGFR1 P11362 1/20 0.51
CYP2C9 P11712 1/20 0.51
EPHB4 P54760 1/20 0.51
PTK2 Q05397 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14286492 0.92 BTK (0.64) CSF1RBTKBRAFLCKKCNQ3
SCHEMBL2491995 0.86 CSF1R (0.84) CSF1RBTKBRAFLCKBLK
SCHEMBL2501240 0.84 CSF1R (0.69) CSF1RBTKBRAFLCKMEN1
SCHEMBL6080388 0.80 CSF1R (0.65) CSF1RBRAFMEN1TSHRKMT2A
SCHEMBL5433359 0.79 TSHR (0.62) CSF1RBTKBRAFLCKMEN1
SCHEMBL5433361 0.79 TSHR (0.62) CSF1RBTKBRAFLCKMEN1
SCHEMBL2496610 0.79 BTK (0.86) CSF1RBTKBRAFLCKBLK
SCHEMBL1276893 0.79 CSF1R (1.00) CSF1RBTKBRAFMEN1TSHR
SCHEMBL2494867 0.78 CSF1R (0.70) CSF1RBTKBRAFLCKMEN1
SCHEMBL2497726 0.78 BTK (0.83) CSF1RBTKBRAFLCKBLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 CSF1R 575/4885BTK 44/4885BRAF 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.